SCOTTSDALE, AZ--(Marketwired - Nov 14, 2013) - QualityStocks today announces the production of stimulating videos featuring International Stem Cell Corp. (
The HD videos can be viewed at http://Video.QualityStocks.net
ISCO was the first to develop and perfect a new class of human stem cells created from unfertilized human eggs. The company's stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
Dr. Simon Craw, EVP of business development, in the videos details ISCO's focus on using these "next-generation" stem cells to treat severe unmet medical needs of the central nervous system and beyond.
"Regenerative medicine has been called the next evolution of medical treatments by the U.S. Department of Health and Human Services. With its potential to heal, this new field of science is expected to revolutionize healthcare," says Dr. Craw.
In mid-2014 ISCO plans to file with the U.S. Food and Drug Administration an investigational new drug (IND) application for Parkinson's disease, a significant achievement that extends far beyond the company's development.
"Filing the IND represents a big step forward for ISCO and a major advancement to the field of Parkinson's disease research," emphasizes Dr. Craw. "We have not only invested in our science but also in our manufacturing and have all the capacity we need to manufacture human cells and related products to support our strategic goals."
Brett Lesser, VP of Sales for LifeLine Cell Technology, one of ISCO's wholly-owned subsidiaries that specializes in manufacturing human cells, explains how ISCO's cellular products are utilized by scientists searching for treatment of a number of other disease.
"Currently our cells are being used in experiments regarding lung cancer, breast cancer, prostate disease, COPD, asthma, diabetes, and a myriad of other life-threatening ailments," states Lesser. "We've grown to a point where scientists from all over the world have published in some of the most prestigious scientific journals about advances in their own while using our cell culture products."
The videos also describe ISCO's self-sustaining business model, subsidiary business units, as well as provides insight on the company's sweeping patent portfolio and investment opportunity.
About International Stem Cell Corp.
International Stem Cell Corp. is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).
More information is available at www.internationalstemcell.com
For more information on International Stem Cell, Inc. visit: http://ISCO.qualitystocks.net
Small Cap Stock Newsletter QualityStocks is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one free Daily Newsletter Report. QualityStocks also utilizes social media and networking to maintain constant communication with its rapidly growing audience.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
The QualityStocks Blog keeps investors up to date on everything related to the Small-Cap and Micro-Cap markets. Alternative fuels and power sources, entertainment media, telecommunications, delivery services, healthcare, and retail are all covered on a regular basis. By visiting our blog, investors also discover emerging companies that they otherwise would not have heard about. To date, more than 30,000 articles have been published via the QualityStocks Blog.
The message board here at QualityStocks is one of the most highly regulated, no-nonsense forums online today; an uncommon haven of highly relevant, SPAM-free investor interaction. Unlike the majority of boards currently in operation, you won't find pumping, bashing, advertising, or malicious posting of any kind here. The QualityStocks Message Boards has over 34,000 registered users.
With all of the stock picks and recommendations available today in the investment world, selecting and deciding on the right stocks can be tedious and time consuming. At QualityStocks, we collate hundreds of investment newsletters into The ONE and ONLY "The QualityStocks Daily", featuring a summary format in which you can view the latest stock picks EVERYDAY.
You can SIGN UP NOW http://Signup.QualityStocks.net
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.